Clinical trials: Head and Neck Cancers- Squamous Cell
Metastatic Cancer, Solid Tumor
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
The study will evaluate the preliminary efficacy of 3 combinations (Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irinotecan) in patients with biliary tract carcinomas (BTC) and with esophageal squamous cell carcinoma (ESCC) by…
- Trial name
- NCT04641871
- Testing
- Sym021, Sym022, Sym023
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 78 people
- Sponsor
- Symphogen A/S
Stage III Oral Cavity Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma
TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Induction chemotherapy is regarded as an effective way to reduce or downgrade the locally advanced or aggressive cancers, and to improve the chance of eradication of the locoregional lesions by radical surgery and/or…
- Trial name
- NCT01542931
- Testing
- TPF induction chemotherapy
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Squamous Cell Carcinoma of the Esophagus
Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy
This is a multicenter, randomized, controlled, open-label phase II study including patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with Fluoropyrimidine and Platinum-based…
- Trial name
- RAMOS (NCT03762564)
- Testing
- Ramucirumab, Paclitaxel
- Where
- 2 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
HNSCC
Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas.
A national, randomized, clinical trial (phase III) investigating radiotherapy with protons compared with photons for patients with squamous cell carcinoma of the head and neck area eligible for radiotherapy, either radical or…
- Trial name
- PRORADNOR-RCT (NCT07580300)
- Testing
- Proton Radiotherapy
- Where
- 4 sites in Norway
- Volunteers
- 400 people
- Sponsor
- Oslo University Hospital
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
This phase II trial examines the use of blood-based biomarkers is to help inform decision making for treatment and radiation therapy for patients with human papillomavirus (HPV) positive oropharyngeal squamous cell cancers.
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT05541016
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 455 people
- Sponsor
- Mayo Clinic
Squamous Cell Carcinoma of the Head and Neck
Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT03855384
- Testing
- TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
- Where
- China
- Volunteers
- 334 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0405 when administered intratumorally in…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
- Trial name
- NCT06273852
- Testing
- PBA-0405
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Pure Biologics S.A.
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx
De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
This randomized, prospective, multicenter phase II/III trial will study the reduction of radiation volume by eliminating radiotherapy (RT) to the elective neck using strictly defined surgical and radio-oncological standards to…
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Hypopharynx, Squamous Cell Carcinoma of the Oropharynx
- Trial name
- DIREKHT2 (NCT06030440)
- Testing
- Eliminating RT to the elective neck, RT standard of care
- Where
- Germany
- Volunteers
- 508 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Head and Neck Cancer
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- CKNO-RERT (NCT00738868)
- Testing
- cetuximab, stereotactic body radiation therapy
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Oscar Lambret
Head and Neck Squamous Cell Carcinoma
Dual-Energy CT in Patients With Head and Neck Squamous Cell Carcinomas
The purpose of this study is to utilize dual-energy computed tomography (DECT) to investigate changes in tumor iodine concentration in patients with head and neck squamous cell carcinomas (HNSCC).
- Trial name
- NCT02279459
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- Ottawa Hospital Research Institute
Esophageal Squamous Cell Carcinoma
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
This trial is a registrational Phase II/III, randomized, controlled, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with tislelizumab ± 5-FU in patients with unresectable, locally…
- Trial name
- NCT07554456
- Testing
- BL-B01D1, Tislelizumab, 5-Fluorouracil
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Head and Neck Squamous Cell Carcinoma
Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab
The primary objective of this study is to determine the clinical performance of UV1 vaccination as add on to standard pembrolizumab treatment in patients with recurrent or metastatic PD-L1 positive (CPS >=1) head and neck…
- Trial name
- FOCUS (NCT05075122)
- Testing
- UV1, Sargramostim for Injection, Pembrolizumab injection
- Where
- 10 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Head and Neck Cancer
Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002888
- Testing
- cisplatin, fluorouracil, paclitaxel
- Where
- 87 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Cancer of Head and Neck
Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma
The objective of this study is to evaluate the efficacity of the combination of cisplatin-5-FU and docetaxel in adapted doses in term of response to treatment without toxicity .
- Trial name
- TPFmORL (NCT04356170)
- Testing
- Docetaxel, Cisplatin, Fluoro Uracil
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin
Skin Cancer Among Outdoor Workers
This observational study examines skin cancer among workers who may have prolonged occupational exposure to sunlight. Long-term exposure to ultraviolet radiation from the sun is an important risk factor for several types of skin…
- Conditions
- Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin, Squamous Cell Cancer of Head and Neck (SCCHN), Work Injury
- Trial name
- Skin Cancer Am (NCT07831083)
- Where
- Israel
- Volunteers
- 10,000 people
- Sponsor
- Assuta Medical Center
Head &Amp; Neck Cancer, Head &Amp; Neck Squamous Cell Carcinoma
Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
This research study is for people who have head and neck cancer that has come back or spread to other places in the body.
- Trial name
- CAPT-HN (NCT07062354)
- Testing
- Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
- Where
- 12 sites in United States
- Volunteers
- 50 people
- Sponsor
- SWOG Cancer Research Network
HNSCC
Dose-Effect Relation of Salivary Gland Irradiation
Optimization of radiotherapy to reduce xerostomia is difficult, because many gland locations cannot be seen with current imaging modalities and biological dose-effect are currently insufficiently understood.
- Trial name
- NCT03367780
- Testing
- PSMA PET/CT-scan
- Where
- 3 sites in Netherlands
- Volunteers
- 32 people
- Sponsor
- The Netherlands Cancer Institute
Head and Neck Cancer, Oropharynx Cancer
Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)
This is a phase II, non-randomized, therapeutic trial with the primary objective to determine the efficacy of reduced contralateral (C/L) elective nodal treatment volumes in preventing C/L recurrences at 2 years in patients with…
- Conditions
- Head and Neck Cancer, Oropharynx Cancer, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- SAVER (NCT04609280)
- Testing
- Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT)
- Where
- 6 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of Maryland, Baltimore
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Advanced Solid Tumor, Locally Advanced Solid Tumor
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC
- Trial name
- NCT04799054
- Testing
- TransCon TLR7/8 Agonist, Pembrolizumab
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 188 people
- Sponsor
- Ascendis Pharma Oncology Division A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.